At Canaritech, we specialize in delivering comprehensive solutions for clinical trials across Latin America. Our multidisciplinary team of experts—comprising doctors, biotechnologists, lawyers, chemists, clinical researchers, and pharmacists—are pioneers in their fields, dedicated to advancing medical research and the development of new treatments. With a deep understanding of local regulations and an extensive regional network, we ensure that our partners’ clinical projects achieve the highest standards of quality, compliance, and innovation.
Our commitment to excellence drives us to offer customized, end-to-end services, from feasibility studies to post-market trials, helping bring groundbreaking medical devices and treatments to market. With a presence in Mexico, Peru, Chile, and Colombia, Canaritech is uniquely positioned to support companies in navigating the complex clinical landscape of Latin America, while fostering sustainable health solutions for the future.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Cdmx, Cdmx, Mx
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Keywords
- cannabis, terapia, ensayos clínicos, CRO, investigación médica, gestión de estudios clínicos, recopilación de datos, medicina.
- HQ
- CDMX, CDMX
Canaritech Questions
Canaritech's website is https://linktr.ee/Canaritech_Official
Canaritech's LinkedIn profile is https://mx.linkedin.com/company/canaritech
Canaritech has
7 employees.
View email and phone details for 7
employees at Canaritech.
Canaritech's industry is
Research Services
Canaritech's top competitors are
Nature Cannabis,
Mbassi Congo,
Greenleaf Medical Clinic,
Ppd,
Bioestadística, S.c.,
Homenurse4u,
Bioveritas,
Udelá Global,
Gigstack (Numera),
Probiomed S.a. De C.v..
Canaritech's categories are Research Services
Canaritech's founding year is 2024
